Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Antonio Palumbo, Roman Hajek, Michel Delforge, Martin Kropff, Maria Teresa Petrucci, John Catalano, Heinz Gisslinger, Wiesław Wiktor-Jędrzejczak, Mamia Zodelava, Katja Weisel, Nicola Cascavilla, Genadi Iosava, Michele Cavo, Janusz Kloczko, Joan Bladé, Meral Beksac, Ivan Spicka, Torben Plesner, Joergen Radke, Christian Langer & 8 others Dina Ben Yehuda, Alessandro Corso, Lindsay Herbein, Zhinuan Yu, Jay Mei, Christian Jacques, Meletios A Dimopoulos, MM-015 Investigators

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma.
Original languageEnglish
JournalThe New England Journal of Medicine
Volume366
Issue number19
Pages (from-to)1759-69
ISSN0028-4793
DOIs
Publication statusPublished - 2012

Fingerprint

Melphalan
Prednisone
Multicenter Studies
Placebos
Maintenance

Keywords

  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols
  • Disease-Free Survival
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Humans
  • Induction Chemotherapy
  • Kaplan-Meier Estimate
  • Maintenance Chemotherapy
  • Male
  • Melphalan
  • Multiple Myeloma
  • Neoplasms, Second Primary
  • Neutropenia
  • Prednisone
  • Thalidomide

Cite this

Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., ... MM-015 Investigators (2012). Continuous lenalidomide treatment for newly diagnosed multiple myeloma. The New England Journal of Medicine, 366(19), 1759-69. https://doi.org/10.1056/NEJMoa1112704
Palumbo, Antonio ; Hajek, Roman ; Delforge, Michel ; Kropff, Martin ; Petrucci, Maria Teresa ; Catalano, John ; Gisslinger, Heinz ; Wiktor-Jędrzejczak, Wiesław ; Zodelava, Mamia ; Weisel, Katja ; Cascavilla, Nicola ; Iosava, Genadi ; Cavo, Michele ; Kloczko, Janusz ; Bladé, Joan ; Beksac, Meral ; Spicka, Ivan ; Plesner, Torben ; Radke, Joergen ; Langer, Christian ; Ben Yehuda, Dina ; Corso, Alessandro ; Herbein, Lindsay ; Yu, Zhinuan ; Mei, Jay ; Jacques, Christian ; Dimopoulos, Meletios A ; MM-015 Investigators. / Continuous lenalidomide treatment for newly diagnosed multiple myeloma. In: The New England Journal of Medicine. 2012 ; Vol. 366, No. 19. pp. 1759-69.
@article{17672b6dd6b64ab6a215bb63d6e7eb08,
title = "Continuous lenalidomide treatment for newly diagnosed multiple myeloma",
abstract = "Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma.",
keywords = "Administration, Oral, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Double-Blind Method, Female, Follow-Up Studies, Humans, Induction Chemotherapy, Kaplan-Meier Estimate, Maintenance Chemotherapy, Male, Melphalan, Multiple Myeloma, Neoplasms, Second Primary, Neutropenia, Prednisone, Thalidomide",
author = "Antonio Palumbo and Roman Hajek and Michel Delforge and Martin Kropff and Petrucci, {Maria Teresa} and John Catalano and Heinz Gisslinger and Wiesław Wiktor-Jędrzejczak and Mamia Zodelava and Katja Weisel and Nicola Cascavilla and Genadi Iosava and Michele Cavo and Janusz Kloczko and Joan Blad{\'e} and Meral Beksac and Ivan Spicka and Torben Plesner and Joergen Radke and Christian Langer and {Ben Yehuda}, Dina and Alessandro Corso and Lindsay Herbein and Zhinuan Yu and Jay Mei and Christian Jacques and Dimopoulos, {Meletios A} and {MM-015 Investigators}",
year = "2012",
doi = "10.1056/NEJMoa1112704",
language = "English",
volume = "366",
pages = "1759--69",
journal = "The New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",
number = "19",

}

Palumbo, A, Hajek, R, Delforge, M, Kropff, M, Petrucci, MT, Catalano, J, Gisslinger, H, Wiktor-Jędrzejczak, W, Zodelava, M, Weisel, K, Cascavilla, N, Iosava, G, Cavo, M, Kloczko, J, Bladé, J, Beksac, M, Spicka, I, Plesner, T, Radke, J, Langer, C, Ben Yehuda, D, Corso, A, Herbein, L, Yu, Z, Mei, J, Jacques, C, Dimopoulos, MA & MM-015 Investigators 2012, 'Continuous lenalidomide treatment for newly diagnosed multiple myeloma', The New England Journal of Medicine, vol. 366, no. 19, pp. 1759-69. https://doi.org/10.1056/NEJMoa1112704

Continuous lenalidomide treatment for newly diagnosed multiple myeloma. / Palumbo, Antonio; Hajek, Roman; Delforge, Michel; Kropff, Martin; Petrucci, Maria Teresa; Catalano, John; Gisslinger, Heinz; Wiktor-Jędrzejczak, Wiesław; Zodelava, Mamia; Weisel, Katja; Cascavilla, Nicola; Iosava, Genadi; Cavo, Michele; Kloczko, Janusz; Bladé, Joan; Beksac, Meral; Spicka, Ivan; Plesner, Torben; Radke, Joergen; Langer, Christian; Ben Yehuda, Dina; Corso, Alessandro; Herbein, Lindsay; Yu, Zhinuan; Mei, Jay; Jacques, Christian; Dimopoulos, Meletios A; MM-015 Investigators.

In: The New England Journal of Medicine, Vol. 366, No. 19, 2012, p. 1759-69.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Continuous lenalidomide treatment for newly diagnosed multiple myeloma

AU - Palumbo, Antonio

AU - Hajek, Roman

AU - Delforge, Michel

AU - Kropff, Martin

AU - Petrucci, Maria Teresa

AU - Catalano, John

AU - Gisslinger, Heinz

AU - Wiktor-Jędrzejczak, Wiesław

AU - Zodelava, Mamia

AU - Weisel, Katja

AU - Cascavilla, Nicola

AU - Iosava, Genadi

AU - Cavo, Michele

AU - Kloczko, Janusz

AU - Bladé, Joan

AU - Beksac, Meral

AU - Spicka, Ivan

AU - Plesner, Torben

AU - Radke, Joergen

AU - Langer, Christian

AU - Ben Yehuda, Dina

AU - Corso, Alessandro

AU - Herbein, Lindsay

AU - Yu, Zhinuan

AU - Mei, Jay

AU - Jacques, Christian

AU - Dimopoulos, Meletios A

AU - MM-015 Investigators

PY - 2012

Y1 - 2012

N2 - Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma.

AB - Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma.

KW - Administration, Oral

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Disease-Free Survival

KW - Double-Blind Method

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Induction Chemotherapy

KW - Kaplan-Meier Estimate

KW - Maintenance Chemotherapy

KW - Male

KW - Melphalan

KW - Multiple Myeloma

KW - Neoplasms, Second Primary

KW - Neutropenia

KW - Prednisone

KW - Thalidomide

U2 - 10.1056/NEJMoa1112704

DO - 10.1056/NEJMoa1112704

M3 - Journal article

VL - 366

SP - 1759

EP - 1769

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

SN - 0028-4793

IS - 19

ER -

Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. The New England Journal of Medicine. 2012;366(19):1759-69. https://doi.org/10.1056/NEJMoa1112704